CardiomyopathiesNCT06893731
Healthcare Utilization and Costs Among Hospitalized Patients With Cardiomyopathy
An observational study of Cardiomyopathies and Cost, run by China National Center for Cardiovascular Diseases at 1 site in China.
Trial summary
Cardiomyopathy is the most common inherited cardiovascular disease, showing family aggregation, and it has a huge psychological and economic burden on family members. In this study, the investigators collected clinical information and costs of patients hospitalized with cardiomyopathy and establish a database to… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cardiomyopathies, Cost
- How many people
- 15,764 participants
- Where
- 1 siteChina
- Study dates
- 1 Mar 2017to 1 Feb 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients hospitalized with cardiomyopathy as the primary discharge diagnosis are recruited retrospectively from multiple centers in China between March 1, 2017 and March 1, 2022.
Who may be able to join
- Hospitalized patients with primary discharge diagnosis meeting one of the following subtypes of cardiomyopathy were enrolled, including HCM, DCM, ACM, RCM, left ventricular non-compaction, cardiac amyloidosis, Fabry disease, Pompe disease, Danon disease, and PRKAG2 cardiac syndrome.
Who cannot join
- Records with a "likely" or "probable" diagnosis of cardiomyopathy were excluded.
Trial locations and contacts
1 site in 1 country.
About this study
Cardiomyopathy is the most common inherited cardiovascular disease, showing family aggregation, and it has a huge psychological and economic burden on family members. In this study, the investigators collected clinical information and costs of patients hospitalized with cardiomyopathy and establish a database to characterize real-world cost profile and inform cost management of cardiomyopathy.
Read the detailed description
This study conducted a retrospective survey of hospitalized patients with cardiomyopathy aged ≥18 years in 13 centers in China from March 1, 2017 to March1, 2022. The investigators collected clinical information, healthcare utilization and cost data of patients hospitalized with cardiomyopathy so as to characterize real-world cost profile and inform cost management of cardiomyopathy in China.
- Conditions
- Cardiomyopathies, Cost
- Medical subject headings
- Cardiomyopathies
What is being measured
The primary outcome is the main question the study is designed to answer.
total cost per hospital admission
Total cost per hospital admissionin is total expenditures made towards a given hospital admission, including the portion paid by the health plan and any out-of-pocket costs paid by enrollees under the plan's cost sharing.The composition of the total cost of hospitalization by categorizing itemized costs into the following groups: total medical consumables cost, total diagnosis-related cost, total treatment cost (e.g., cost of operation), total Western medicine cost, total services cost, total blood and blood products cost, total traditional Chinese medicine cost, total traditional Chinese treatment cost, total rehabilitation cost, and other costs.
Measured: through hospitalization completion, an average of 10 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Mar 2025
- Study start1 Mar 2017
- Primary completion1 Mar 2022
- Study completion1 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CardiomyopathiesStudies of the same condition, open and under way.
- More trials run by China National Center for Cardiovascular DiseasesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 15,764 participants (actual)
Sponsor and investigators
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Lei.Song,MD.&ph.D, China National Center for Cardiovascular Diseases
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06893731
- Sponsor's protocol ID
- 2023-ZX005
- Status last verified
- Apr 2026
- First submitted
- 27 Sep 2024
- Last updated
- 20 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 20 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Healthcare Utilization and Costs Among Hospitalized Patients With Cardiomyopathy
- ClinicalTrials.gov ID
- NCT06893731
- Acronym / sponsor ID
- 2023-ZX005
- Conditions
- Cardiomyopathies, Cost
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 15,764 participants (actual)
- Lead sponsor
- China National Center for Cardiovascular DiseasesOther government
- Study start
- 1 Mar 2017 (actual)
- Primary completion
- 1 Mar 2022 (actual)
- Study completion
- 1 Feb 2026 (actual)
- First posted
- 25 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cardiomyopathy is the most common inherited cardiovascular disease, showing family aggregation, and it has a huge psychological and economic burden on family members. In this study, the investigators collected clinical information and costs of patients hospitalized with cardiomyopathy and establish a database to characterize real-world cost profile and inform cost management of cardiomyopathy.
Detailed description
This study conducted a retrospective survey of hospitalized patients with cardiomyopathy aged ≥18 years in 13 centers in China from March 1, 2017 to March1, 2022. The investigators collected clinical information, healthcare utilization and cost data of patients hospitalized with cardiomyopathy so as to characterize real-world cost profile and inform cost management of cardiomyopathy in China.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients hospitalized with cardiomyopathy as the primary discharge diagnosis are recruited retrospectively from multiple centers in China between March 1, 2017 and March 1, 2022.
Key inclusion criteria (1 listed)
- Hospitalized patients with primary discharge diagnosis meeting one of the following subtypes of cardiomyopathy were enrolled, including HCM, DCM, ACM, RCM, left ventricular non-compaction, cardiac amyloidosis, Fabry disease, Pompe disease, Danon disease, and PRKAG2 cardiac syndrome.
Key exclusion criteria (1 listed)
- Records with a "likely" or "probable" diagnosis of cardiomyopathy were excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
total cost per hospital admission
Time frame: through hospitalization completion, an average of 10 days
Total cost per hospital admissionin is total expenditures made towards a given hospital admission, including the portion paid by the health plan and any out-of-pocket costs paid by enrollees under the plan's cost sharing.The composition of the total cost of hospitalization by categorizing itemized costs into the following groups: total medical consumables cost, total diagnosis-related cost, total treatment cost (e.g., cost of operation), total Western medicine cost, total services cost, total blood and blood products cost, total traditional Chinese medicine cost, total traditional Chinese treatment cost, total rehabilitation cost, and other costs.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 May 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Cardiomyopathies
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
Active, not recruitingObservational study
A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany
ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiomyopathies and Cost, run by China National Center for Cardiovascular Diseases at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
total cost per hospital admission (time frame: through hospitalization completion, an average of 10 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2026.